Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
IMpactMF
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
- NCT04576156 ↗
- Active, not recruiting
- Geron Corporation
- Deep
We haven't built an HCP commentary report on IMpactMF (imetelstat and best available therapy in Myelofibrosis) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMpactMF so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 18 | |
| Podcasts | 11 | |
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Myelofibrosis
- Interventions
- Imetelstat; Best Available Therapy (BAT)
- Arms
- Imetelstat · Experimental
- Best Available Therapy (BAT) · Active comparator
- Enrollment
- 327
- Primary outcomes
- Overall survival (OS)
- Sponsor
- Geron Corporation
- Start
- Apr 12, 2021
- Primary completion
- Jun 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04576156 · updated Jul 8, 2026
Publications
linked from the registry- Mascarenhas J, Harrison CN, Kiladjian JJ, Komrokji RS, Koschmieder S, Vannucchi AM, Berry T, Redding D, Sherman L, Dougherty S, Peng L, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Verstovsek S. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol. 2022 Jul;18(22):2393-2402. doi: 10.2217/fon-2022-0235. Epub 2022 May 5. PubMed 35510486